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Abstract
Paracoccidioidomycosis is a systemic fungal disease occurring in Latin America that is associated with rural environments and 
agricultural activities. However, the incidence and prevalence of paracoccidiodomycosis is underestimated because of the lack 
of compulsory notification. If paracoccidiodomycosis is not diagnosed and treated early and adequately, the endemic fungal 
infection could result in serious sequelae. While the Paracoccidioides brasiliensis (P. brasiliensis) complex has been known to 
be the causal agent of paracoccidiodomycosis, a new species, Paracoccidioides lutzii (P. lutzii), has been reported in Rondônia, 
where the disease has reached epidemic levels, and in the Central West and Pará. Accurate diagnoses and availability of antigens 
that are reactive with the patients’ sera remain significant challenges. Therefore, the present guidelines aims to update the first 
Brazilian consensus on paracoccidioidomycosis by providing evidence-based recommendations for bedside patient management. 
This consensus summarizes etiological, ecoepidemiological, molecular epidemiological, and immunopathological data, with 
emphasis on clinical, microbiological, and serological diagnosis and management of clinical forms and sequelae, as well as in 
patients with comorbidities and immunosuppression. The consensus also includes discussion of outpatient treatments, severe 
disease forms, disease prevalence among special populations and resource-poor settings, a brief review of prevention and control 
measures, current challenges and recommendations.
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FIGURE 1 - Geographic distribution of Paracoccidioides lutzii and 
Paracoccidioides brasiliensis cryptic species. Modified (update on P. lutzii 
distribution) from: Muñoz JF, Farrer RA, Desjardins CA, Gallo JE, Sykes S, 
Sakthikumar S, et al. Genome diversity, recombination, and virulence across 
the major lineages of Paracoccidioides. mSphere 2016; 1(5): e00213-163. PS2; 
PS3; PS4; S1a; S1b: phylogenetic species of Paracoccidioides brasiliensis; Pl: 
Paracoccidioides lutzii.
ETIOLOGY
Paracoccidioidomycosis (PCM) is caused by thermo-
dimorphic fungi that currently encompasses two species: 
Paracoccidoides brasiliensis (P. brasiliensis) and 
Paracoccidioides lutzii (P. lutzii)1. P. brasiliensis contains a 
complex of at least five phylogenetic clusters ranked as the 
following phylogenetic species: S1a, S1b, PS2, PS3, and PS42,3,4. 
The phylogenetic species S1a and S1b are predominantly found 
in lower South America, especially in southeastern and southern 
Brazil, Argentina, and Paraguay. The PS2 species has a sporadic 
distribution and is less frequently reported, with human cases 
only being reported thus far in Venezuela and southeast Brazil 
(Figure 1). The PS3 and PS4 species are exclusively endemic 
to Colombia and Venezuela, respectively. P. lutzii encompasses 
a single species and is predominantly distributed in the Central 
West and Amazon regions of Brazil and Ecuador1,5,6,7,8. However, 
the real incidence of each phylogenetic species and its implication 
on clinical practice is difficult to establish because of the lack 
of guided studies comparing PCM forms and manifestations 
with their genetic background9. Radial immunodiffusion 
against the commonly used exoantigens containing a 43-kDa 
glycoprotein (gp43) suggests that Paracoccidiodes spp. exhibit 
major antigenic variability. According to phylogenetic studies, 
different Paracoccidioides spp. isolates are distributed in 
different genotypes across multiple PCM endemic areas of 
Latin America. In particular, Paracoccidioides spp. in central 
Brazil (i.e. Mato Grosso and Rondônia) exhibit a lower rate of 
genetic similarity. Yet, P. lutzii isolates exhibit high species-
specific antigen variability9, which has already been assessed 
in proteomic studies.
ECOEPIDEMIOLOGY
In nature, P. brasiliensis and P. lutzii develop as filamentous 
structures and produce infective propagules called conidia10,11 
(Figure 2). If inhaled, the propagules give rise to yeast forms of 
the fungus that become parasitic to the host. Paracoccidioides 
spp. can cause infection and disease in humans and domestic 
and wild animals, although only a few active disease cases have 
been observed in animals, such as dogs10,12. The armadillo is 
known to be a reservoir of P. brasiliensis, and the fungus can 
be easily cultured from the animal’s internal organs (spleen, 
liver, and lymph nodes), indicating a systemic process. P. lutzii 
has not yet been isolated from armadillos. 
Epidemic outbreaks of PCM have never been observed. 
Further, fungal recovery (culture) directly from the fungi’s 
environmental saprophytic form has been shown to be 
particularly difficult to obtain with reproducibility. Thus, the 
region where the disease is acquired is referred to as reservaria. 
Yet, sensitive molecular screening techniques have detected the 
fungus in soils and aerosols, especially among samples taken 
from animal burrows or sites with medium to high moisture 
content protected by vegetation cover13.
In recent decades, changes in the demographic characteristics 
and geographical distribution of PCM incidence have been 
observed. These shifts could be attributed to the rise of 
urbanization, application of diagnostic methods, and the 
presence of comorbidities and immunosuppression. In addition, 
environmental factors, such as the expansion of settlements, 
clearing of forests, and increased coffee production, could 
contribute to the current high levels of PCM incidence in some 
regions of Rondônia14.
In addition, between 1982 and 1983, a region of Southeast 
Brazil experienced climatic changes related to El Niño, resulting 
in elevated soil moisture levels and temperatures between 
18-28ºC, which are favorable for fungal sporulation and aerial 
dispersion. During this same time period, the region experienced 
an outbreak of acute cases of PCM15.
How is Paracoccidioides infection acquired?
The major risk factor for acquiring infection is a profession 
or activity related to the management of soil contaminated with 
the fungus, such as agriculture, earthworks, soil preparation, 
gardening, and transportation of vegetable products (Figure 2). 
In a majority of all PCM infection cases the patients had been 
exposed to agricultural activities during the first two decades of 
their life, at which point they likely acquired the infection even 
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FIGURE 2 - Spread of Paracoccidioides brasiliensis and Paracoccidioides lutzii. Pb: Paracoccidioides brasiliensis; Pl: Paracoccidioides lutzii.
if clinical manifestations appeared many years later11. Most of 
these patients seeked medical attention many years after they 
left the endemic area and resided in urban centers where were 
engaged in other activities unrelated to soil management. For 
example, smoking (> 20 cigarettes/day for > 20 years) and 
alcoholism (> 50g/day)16 are frequently associated with mycosis. 
Unlike other mycoses, such as cryptococcosis, disseminated 
histoplasmosis, and candidiasis, PCM is not usually related 
to immunosuppressive diseases. However, cases of PCM 
associated with HIV infection, neoplasia and, more rarely, 
organ transplants and use of immunobiologicals have been 
reported17-20.
Incidence, prevalence and mortality
Since PCM is not a compulsory notification disease, 
we do not have precise data on its incidence in Brazil. 
Mycosis prevalence, incidence, and morbidity estimates are 
based on reports from epidemiological surveys, case series, 
hospitalization records, and mortality data21. Based on the 
experiences of reference services caring for patients with PCM, 
the disease’s incidence in endemic areas ranges from three to 
four new cases per one million inhabitants and one to three new 
cases per 100,000 inhabitants per year. About 80% of PCM cases 
are registered in Brazil, particularly in the States of São Paulo, 
Paraná, Rio Grande do Sul, Goiás, and Rondônia (Figure 3)21. In 
Latin America, cases are most frequently reported in Argentina, 
Colombia, Venezuela, Ecuador, and Paraguay. Estimates of 
annual incidence in Brazil range from 0.71 to 3.7 cases per 
100,000 inhabitants21. However, recent records of incidence in 
Rondônia report 9.4 cases per 100,000 inhabitants, with two 
municipalities reporting incidences close to 40 cases per 100,000 
inhabitants14. Between 1980 and 1995, the Ministry of Health 
documented 3,181 cases of PCM-related deaths, resulting in a 
PCM mortality rate of 1.45 cases per one million inhabitants 
(2.59 for the South, 2.35 for the Midwest, 1.81 for the Southeast, 
1.08 for the North, and 0.2 for the northeast regions)22. In this 
study, among all chronic infectious and parasitic disease, PCM 
was listed as the eighth highest cause of mortality and had the 
highest mortality rate among the systemic mycoses, even having 
a higher mortality rate than leishmaniasis. Recent data collected 
from 13,683 patients who were hospitalized with systemic 
mycoses between January 1998 and December 2006 showed 
that PCM accounts for the largest number of hospitalizations 
(49%) among all mycoses23, with emphasis on hospitalization 
rates in the north and Midwest regions, without major difference 
in the mortality of hospitalized patients (Figure 3).
Age group and distribution between genders
PCM infection is primarily acquired in the first two decades 
of life, with a peak incidence between 10 and 20 years of age. 
However, the presentation of clinical manifestations or evolution 
to disease is uncommon in this age group. Instead, PCM 
occurs more frequently in adults between the ages of 30- and 
50-years-old as a result of endogenous latent foci reactivation10. 
Although the frequency of PCM cases ranges between regions, 
an estimated 10% of PCM cases occur in individuals under the 
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FIGURE 3 - Geographical areas of paracoccidioidomycosis endemicity in Latin America. Reproduction from: Martinez R. New trends in Epidemiology. J Fungi. 
2017;3(1):121.
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age of 20-years-old, while the remaining 90% occurring later in 
life. Further, in childhood, the frequency of PCM cases is evenly 
distributed between both genders, with a slight predominance in 
young male adults; however, in adulthood, the frequency ranges 
from ten to 15 men for one woman.
IMMUNOPATHOGENESIS
Control of Paracoccidioides spp infection depends on the 
host´s cellular immune response, with T cells playing a prominent 
role. PCM has a range of clinical presentations along a spectrum, 
with each one being potentially associated with a specific T cell 
immunity pattern24. Most infected individuals living in endemic 
areas will not develop any illness. These individuals exhibit a 
T-helper [Th-1] immune response pattern characterized by the 
release of cytokines that activate macrophages, TCD4+, and 
TCD8+ cells, resulting in the formation of compact granulomas 
and control of fungal replication25,26; however, dormant forms 
of the fungus may still exist inside these granulomas. The few 
individuals who do develop the disease most likely had deficient 
Th-1 responses, with the extent of the failure correlating with 
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disease severity25,26. In fact, patients with infections that evolve 
to the more severe forms, such as the acute/subacute form 
disease (A) or eventually the severe disseminated chronic 
form (CF), develop Th-2 and Th-9 immune response patterns 
that do not form compact granulomas, but instead activate 
B lymphocytes, high levels of specific antibodies, including the 
the IgE subclass, hypergammaglobulinemia, and eosinophilia27. 
Patients with the severe/disseminated unifocal or multifocal 
CF who bear lower fungal burdens, also exhibit deficient Th-1 
responses, often at a lesser degree that that of patients with 
the AF or severe disseminated CF. In addition, these patients 
can still experience the formation of compact granulomas 
that can suppress, at least partially, fungal replication25,26. In 
these patients, the loss of Th-1 function would be partially 
compensated by the development of Th-17 and Th-22 responses, 
both of which drive intense mucosal inflammatory responses 
rich in neutrophils27. In fact, a characteristic feature of the CF 
is the involvement of the mucosa, especially in the respiratory 
tract. In addition, it has been demonstrated that regulatory 
T cells (Tregs) suppress T cell immunity and contribute to the 
T cell anergy observed in the more severe forms of the disease28,29.
The factors that determine the different outcomes of the 
PCM host-parasite interaction remain unknown. Preliminary 
data suggest that the host’s immunogenetic background may 
play a role30. Regardless, clinical experiences have indicated 
that treatment of PCM should persist for long periods until 
effective cellular immune responses are elicited. However, for 
unknown reasons, yeast cells may remain in quiescent foci that 
can reactivate the disease and cause relapses. Usually, immune 
alterations subside with treatment and the protective Th-1 
responses appear/reappear. This observation is corroborated 
by in vitro experiments that have demonstrated deficient Th-1 
responses can be reverted31, although this response reconstitution 
has not been shown to reach the magnitude of that observed in 
healthy individuals without disease32. The role of the observed 
high serum levels of specific antibodies in any mechanism of 
protection could not yet be determined. 
CLASSIFICATION OF CLINICAL FORMS 
AND ASSESSMENT OF SEVERITY
PCM can compromise any organ, apparatus or system, as 
revealed in Table 133,34, which presents clinical and autopsy 
findings. Further, PCM’s diversification tends to hinder its 
classification.
Several classifications of PCM clinical forms have been published 
based on different criteria, such as lesion topography, disease natural 
history, severity of clinical presentation, and serological reaction 
results. This consensus adopted the classification presented in the 
International Colloquium on Paracoccidioidomycosis held in 
February 1986 in Medellin, Colombia35.
I.Paracoccidioidomycosis infection
II.Paracoccidioidomycosis (disease)
A. Acute/subacute form (juvenile)
• - Moderate
• - Severe
B. Chronic form (adult) 
• - Mild
• - Moderate
• - Severe
III. Residual form or sequelae
Paracoccidioidomycosis infection
Paracoccidioidomycosis infection is contracted when a 
healthy individual comes into contact with a Paracoccidioides 
spp. The infection is diagnosed by a positive intradermal reaction 
to specific antigens and necropsy findings of latent fungi36. 
Clinical forms of Paracoccidioidomycosis
Acute/subacute form (juvenile)
The acute/subacute form of PCM is responsible for 5-25% 
of cases and may be more frequent in certain endemic regions 
while almost never observed in others. In Brazil, this form is 
more commonly observed in the following States: Maranhão, 
Minas Gerais, Pará, Goiás, and São Paulo. 
The incidence of PCM appears to be declining in some 
endemic areas37. Acute/subacute PCM predominantly affects 
children, adolescents, and young adults, but can occur in adults 
between the ages of 30- and 40-years-old. The incidence of 
PCM tends to be evenly distributed between genders, especially 
among the adolescent population33,37-39.
This clinical form of PCM rapidly evolves and disseminates 
the infection to multiple organs and systems. In general, 
patients are diagnosed within a few weeks of symptoms 
onset. Most symptoms involve the phagocytic-mononuclear 
system, including the presence of localized or generalized 
lymphadenomegaly, which may present suppuration, fistulization, 
and hepatosplenomegaly. Symptoms may also include digestive 
manifestations, cutaneous (or mucosal) lesions, osteoarticular 
involvement, and rarely, pulmonary involvement. Fever, weight 
loss, and anorexia often accompany the clinical presentation. 
Intra-abdominal lymphadenomegaly may coalesce, producing 
tumor masses that exert compression on various organs, such 
as the bile duct and intestinal loops38 (Figure 4 and Figure 5). 
A prominent finding of laboratory alterations in this form is 
peripheral eosinophilia, which occurs in 30% to 50% of cases38-40. 
Under certain conditions, eosinophilia may be significant (up to 
70% of peripheral blood leukocytes).
Chronic form (adult)
The majority (74% to 96%) of PCM cases are in chronic 
form, which typically manifests in adults between the ages of 
30- and 60-years-old (male to female ratio: 22:1). Chronic PCM 
initiates slowly and the symptoms often persist beyond 4 to 6 
months, possibly even a year. In some cases, PCM develops 
without any physical indication, and the infection is only caught 
when the individual goes for a routine check-up or labor-related 
physical examinations. In 90% of patients with PCM, pulmonary 
impairment is observed41,42. After the lungs, the organs most 
affected by PCM are the mucosa of the upper aerodigestive 
pathway and skin (Figure 6 and Figure 7). 
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Organs Clinical manifestation Necropsies
Belissimo-Rodrigues  
et al [33]*
Franco et al [34]** Franco et al [34]**
n % n % n %
Lungs 778 63.8 128 74.0 24 96.0
Bronchus/trachea 5 0.4 . . .
Lymphadenomegaly
generalized
localized
618
342
276
28.1
22.6
63 36.4 18 72.0
Mouth, pharynx, larynx
oral mucosa
larynx
610
196
50.0
16.1
83 48.0 15 60.0
nasal mucosa 19 1.6
Adrenals 26 2.1 6 3.5 11 44.0
Central Nervous System (CNS) 42 3.4 1 0.6 9 36.0
Liver 0 0.0 8 32.0
Spleen 57 4.7 0 0.0 7 28.0
Skin 361 29.6 22 12.7 6 24.0
Kidney 0 0.0 4 16.0
Bone marrow 0 0.0 3 12.0
Heart 0 0.0 3 12.0
Digestive tract 92 7.5 6 6.5 2 8.0
Testicles 9 0.7 1 0.6 2 8.0
Prostate 1 0.6 2 8.0
Eyes 2 1.2 0 0.0
Breast 1 0.6 0 0.0
Osteoarticular 27 2.2
TABLE 1
Organs affected in paracoccidioidomycosis.
A B C D
FIGURE 4 - Acute form of PCM in children. A. Abscesses in frontal and clavicular regions resulting from osteo-articular involvement. B. Female child presenting 
with abscessed lymphatic involvement. C. Inguinal lymphoadenomegaly. D. Lymphatic-abdominal involvement with ascites and hepatosplenomegaly. PCM: 
paracoccidioidomycosis. Reproduction with modification: Shikanai-Yasuda MA, Telles Filho F de Q, Mendes RP, Colombo AL, Moretti ML, Grupo de Consultores 
do Consenso em Paracoccidioidomicose. Consenso Brasileiro em Paracoccidioidomicose. Rev Soc Bras Med Trop. 2006;39(3):297-31039.
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*1,219 patients of the Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP). ** 173 patients and 25 necropsies at the Faculdade de 
Medicina de Botucatu, Universidade Estadual Paulista (UNESP).
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FIGURE 5 - Patients with the acute/subacute (juvenile) form of PCM. A. Ganglionic mass in supraclavicular, cervical, and submandibular region. B. 
Lymphadenomegaly of PCM, which must be differentiated from hematological diseases, such as lymphoma. C. Verrucous ulcerative lesions on the face and 
pavilion caused by hematogenous dissemination. D. Papulonodular ulcerative lesions caused by hematogenous dissemination. PCM: paracoccidioidomycosis. 
Reproduction with modification: Shikanai-Yasuda MA, Telles Filho F de Q, Mendes RP, Colombo AL, Moretti ML, Grupo de Consultores do Consenso em 
Paracoccidioidomicose. Consenso Brasileiro em Paracoccidioidomicose. Rev Soc Bras Med Trop. 2006;39(3):297-31039.
A B
FIGURE 6 - Oral involvement in chronic PCM 47,48. A. Gingivostomatitis. 
B. Moriform stomatitis of Aguiar-Pupo. The lesions may present as extensive, 
ulcers, or ulcer-vegetative, with characteristic hemorrhagic dots (moriform 
lesion). Although infrequent, the lesions may extend into the nasal vestibule, 
causing perforation of the palate and nasal septum, with inaesthetic and 
functional sequelae. In acute PCM, the oral mucosa is not frequently involved. 
PCM: paracoccidioidomycosis. Reproduction with modification: Shikanai-
Yasuda MA, Telles Filho F de Q, Mendes RP, Colombo AL, Moretti ML, Grupo 
de Consultores do Consenso em Paracoccidioidomicose. Consenso Brasileiro 
em Paracoccidioidomicose. Rev Soc Bras Med Trop. 2006;39(3):297-31039.
Chronic PCM can be classified as either mild, moderate, or 
severe35. Severe cases are defined by meeting three or more of the 
following criteria: a) weight loss greater than 10% of the normal 
body weight; b) intense pulmonary involvement; c) involvement of 
other organs, such as adrenal glands, central nervous system, and 
bones; d) the presence of lymph nodes affected in multiple chains 
in superficial or deep, pseudotumoral form (>2.0cm in diameter, 
without suppuration) or suppurative form; e) high antibody titers. 
In fact, severe cases are represented by patients presenting 
clinical instability due to respiratory insufficiency, adrenal 
dysfunction, neurological syndrome or acute abdomen. 
Mild cases, which constitute a small portion of patients, are those 
with weight loss below 5% of normal body weight and involvement 
of unique or a few organs or tissues without disfunction.
In some cases, patients present with clinical manifestations 
of both acute/subacute and chronic forms, making it difficult 
to properly classify the disease. Most of these patients present 
with intense suppression of cellular immunity and are labelled 
as having mixed form PCM43.
Residual forms (sequelae)
Residual forms, also referred to as sequelae, are clinical 
manifestations of anatomical and functional changes observed 
FIGURE 7 - Clinical aspects of chronic PCM. A. Papulonodular ulcerative lesions on the face. B. Perioral and mentonian involvement. C. Fistulated cervical 
and submandibular lymph nodes. D. Vegetative lesion with irregular borders in the perianal region. Through hematogenous dissemination, especially traumatic 
fungal implantation, the cutaneous lesions contiguously develop from compromised mucosa, fistulated lymph nodes, or bone involvement47. The lesions are 
characterized by ulcero-crusted polymorphisms, molluscoids, papules, or acneiforms, and are located primarily in the cephalic pole and periorificial regions48. 
Of note, patients with Addison's syndrome typically present with cutaneous and mucosal hyperpigmentation. PCM: paracoccidioidomycosis. Reproduction with 
modification: Shikanai-Yasuda MA, Telles Filho FQ, Mendes RP, Colombo AL, Moretti ML, Grupo de Consultores do Consenso em Paracoccidioidomicose. 
Consenso Brasileiro em Paracoccidioidomicose. Rev Soc Bras Med Trop. 2006;39(3):297-31039. 
after PCM treatment. Sequelae are observed in multiple organs, 
but have a higher rate of incidence in the lungs, skin, larynx, 
trachea, adrenals, mucosa of the upper aerodigestive tract, 
central nervous system, and lymphatic system, thus explaining 
the diversity of clinical presentation44-46.
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INITIAL TREATMENT, DIAGNOSTIC  
APPROACH, AND OUTPATIENT  
FOLLOW-UP ROUTINE OF PATIENTS 
WITH PCM
Since PCM is systemic, any organ can be affected. The 
attention of the observer should initially be directed to the 
general condition of the patient and then the organs and systems 
that are most frequently committed according to the forms of 
the disease presentation: acute/subacute PCM and chronic 
PCM. According to routine medical care, all patients should 
have a detailed physical examination, reporting weight and 
height evaluation, to allow the characterization of nutritional 
status. 
General evaluation of a patient with  
acute/subacute form
In acute/subacute PCM, anamnesis and physical 
examination play an important role in the determination of 
disease severity and systemic involvement. For example, the 
presence of lymphadenomegaly in various lymphatic chains, 
hepatosplenomegaly, cutaneous lesions, or abdominal masses 
can be confirmed during a patient’s physical examination. In 
addition, clinical examination can also detect the presence 
of jaundice, ascites, and peripheral edema, which prompt 
investigation of hypoalbuminemia. In acute/subacute PCM, 
signs of adrenal and neurological involvement are rare. Fever, 
weight loss, and digestive complaints, such as abdominal pain, 
chronic malabsorptive diarrhea, and vomiting, are also quite 
frequent40. The presence of tumefaction or pain in the bone 
region requires the identification of bone lesions. 
Laboratory tests and imaging:
Chest X-ray (posterior, anterior, profile)
Complete blood count and erythrocyte sedimentation rate (ESR)
Liver biochemical tests (alanine aminotransferase (ALT), 
alkaline phosphatase)
Total proteins and fractions
Evaluation of renal and metabolic function (serum creatinine, Na, K)
Imaging tests, such as ultrasound, CT, magnetic resonance 
imaging (MRI), and scintigraphic mapping should only be 
performed when there is clinical suspicion or laboratory results 
suggestive of organ involvement that cannot be solely assessed 
by physical examination.
General evaluation of a patient with chronic form
In chronic PCM, anamnesis and physical examination 
must include the evaluation of signs and symptoms related 
to pulmonary, tegumentary, and laryngeal involvement41,46 
(cough, dyspnea, mucus/purulent expectoration, ulcerated 
lesions of the skin and naso-oropharyngeal mucosa47,48, 
odynophagia, dysphagia, and dysphonia). Both diagnostic 
methods must also evaluate signs and symptoms of lymphatic 
adenomegaly, adrenal involvement49,50 (asthenia, weight 
loss, hypotension, skin darkening, abdominal pain), central 
nervous system involvement51,52 (headache, motor deficit, 
convulsive syndrome, and alteration of behavior and/or level 
of consciousness), and digestive impairment (diarrhea and 
malabsorption syndrome)53,54 (Figure 8). 
A B
C D
E F
FIGURE 8 - Images of PCM. A. Conventional butterfly wing radiological 
image showing bilateral, parahilar, and symmetrical pulmonary involvement 
with a predominance of alveolar lesions, sparing apices and lower thirds. These 
manifestations are very suggestive of PCM but occur infrequently. B. Diffuse and 
symmetric nodular and micronodular opacities. C. Computed tomography (CT) of 
lungs with multiple sub-pleural cavities. Pulmonary lesions may be interstitial of the 
thin or coarse reticular-nodular type, or, less frequently of the tumor type. D. Bilateral 
adrenal increase. E and F. CNS: hypodense and ring-shaped contrast enhancement 
images with small mass effect. PCM: paracoccidioidomycosis. Reproduction with 
modification: Shikanai-Yasuda MA, Telles Filho F de Q, Mendes RP, Colombo AL, 
Moretti ML, Grupo de Consultores do Consenso em Paracoccidioidomicose. Consenso 
Brasileiro em Paracoccidioidomicose. Rev Soc Bras Med Trop. 2006; 39(3): 297-31039.
Laboratory tests and imaging 
Chest X-rays (posterior, anterior, profile)
Complete blood count and erythrocyte sedimentation rate (ESR)
Liver biochemical tests (ALT, alkaline phosphatase)
Evaluation of renal and metabolic function (serum creatinine, Na, K) 
More complex examinations should be conducted if there 
is a clinical suspicion or laboratory result suggesting central 
nervous system involvement, gastrointestinal involvement, 
abdominal forms, chronic respiratory insufficiencies, or 
osteo-articular lesions. In patients presenting with these signs, 
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imagining and functional tests should be performed under 
the guidance of medical experts. Given the high frequency of 
adrenal involvement and its clinical impact, patients suspected 
of having chronic PCM should undergo an assessment of the 
functional reserve when available. 
Differential diagnosis
Other conditions to consider in the differential diagnosis 
for PCM include the following: acute lymphoma, leukemia, 
histoplasmosis, tuberculosis, toxoplasmosis, visceral 
leishmaniasis, and infectious mononucleosis. For chronic 
cutaneous-mucosal PCM, the conditions to consider in the 
differential diagnosis are cutaneous or mucosal leishmaniasis, 
tuberculosis, chromoblastomycosis, leprosy, sarcoidosis, lues, 
neoplasia and in the chronic pulmonary form, tuberculosis 
(Table 2)55, coccidioidomycosis, histoplasmosis, sarcoidosis, 
pneumoconiosis, and interstitial pneumonitis. For digestive 
Epidemiology Tuberculosis Paracoccidioidomycosis
Age Wide range Restricted (30- to 60-years-old)
Gender Indistinct Prevalent in males (15:1)**
Incidence 45/100,000 1-3/100,000
Mortality 2.3/100,000 1.65/1,000,000
Geographic distribution Worldwide, more urban Latin America, more rural
Microbiology
etiologic agent Mycobacterium tuberculosis Paracoccidioides spp.
source of infections Man/animal Soil
infection Contagious Non-contagious
cultivation Fastidious Fastidious
Clinical aspects
signs and symptoms Well defined Non-specific
weight loss ++/++++ ++/++++
fever ++++ +/-***
cough ++++ +/-
hemoptoic sputum +++/++++ +/-
pleural involvement Yes No
association PCM (10-15%) TB (10-15%)
Radiology
image localization Predominance in upper zone Predominance in medium thirds, bilateral, and 
diffuse zones
cavities +++/++++ ++/++++
pleural images Yes No
dissemination Uni/multifocal Uni/multifocal
Laboratorial changes
red cells Normocytic normochromic anemia Normocytic normochromic anemia
white cells Leukocytosis/leukopenia Leukocytosis/leukopenia
ESR +++/++++ +/++
serum proteins Normal/low Normal/low
Natural evolution +++ +++
consumption Yes Yes
anergy Yes Yes
death Yes Yes
* Modified from: Queiroz-Telles F and Escuissato D. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med. 2011;32:764-7455. **Pneumonia may occur 
rarely in acute/subacute PCM. In these cases, both sexes can be affected; ***Fever may occur in patients with associated infections. PCM: paracoccidioidomycosis; 
TB: tuberculosis; ESR: erythrocyte sedimentation rate.
TABLE 2
Pulmonary involvement: differences between tuberculosis and paracoccidioidomycosis*.
PCM, conditions to consider in the differential diagnosis are 
tuberculosis and Chron’s disease, while for forms of PCM 
that affect the central nervous system, the conditions are 
tuberculosis, cryptococcosis, cysticercosis, and neoplasias. 
Laboratory examinations for specific diagnosis
The identification of Paracoccidioides spp. through the 
examination of fresh sputum or other clinical specimens, such 
as lesion sample, lymph node aspiration, or biopsy fragment, 
is the gold standard for PCM diagnosis. 
Aspects of PCM laboratory diagnosis are presented in 
Figure 9. 
In an attempt to standardized PCM diagnosis, the following 
definitions are offered: 
Suspected case: patient presents with one or more of the 
following manifestations, excluding tuberculosis and other 
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diseases that occur with a similar condition, for at least four 
weeks:
• Cough with or without sputum and dyspnea
• Sialorrhea, odynophagia, or hoarseness
• Lesion (ulcerated) in the nasal or oral mucosa
• Skin lesions (ulcers, vegetation, nodules, plaques, etc.)
• Cervical or generalized adenomegaly, with or without 
suppuration and fistulization. 
• Child or young adult with hepatosplenomegaly and/or 
abdominal tumefaction
Probable case: a patient with clinical manifestations 
compatible with PCM and anti-P. brasiliensis/P. lutzii serum 
antibody titers detected preferably by quantitative double 
immunodiffusion test or counterimmunoelectrophoresis. 
Confirmed case: Patient with clinical manifestations 
compatible with PCM with secretions, bodily fluids, or 
lesion material presenting with fungal elements suggestive 
of P. brasiliensis/P. lutzii infection (Figure 9). Note, the 
micromorphology of P. brasiliensis/P. lutzii parasitic forms in 
the biological material of infected patients cannot distinguish 
between the two species. Therefore, the identification of the 
involved species requires culture isolation and application of 
molecular techniques56,57.  
A B
C D
E F
FIGURE 9 - Laboratory diagnosis of paracoccidioidomycosis. A and B. 
Cultivation of P. brasiliensis. A. mycelial phase. B. yeast phase. C. Fresh 
examination in KOH. D. Lactophenol staining showing yeast cells with multiple 
buds. E. Histological section stained by the Grocott method. F. Histological 
section stained by PAS. KOH: Potassium hydroxide; PAS: Periodic acid - Schiff 
stain. Reproduction with modification: Shikanai-Yasuda, MA, Telles Filho F de 
Q, Mendes RP, Colombo AL, Moretti ML, Grupo de Consultores do Consenso 
em Paracoccidioidomicose. Consenso Brasileiro em Paracoccidioidomicose. 
Rev Soc Bras Med Trop. 2006;39(3):297-31039.
Critical evaluation of serological tests:  
serologic diagnosis and follow-up 
Specific serological tests are important in not only the 
diagnosis of PCM, but also in the assessment of host response to 
specific treatments. Currently, double immunodiffusion (DID), 
counterimmunoelectrophoresis (CIE), immunoenzymatic 
assays (ELISA), and immunoblots (IB) are the serological 
tests available in different reference services58-60. 
These tests use standardized techniques and adequate 
antigens61, and display a sensitivity between 80% and 95%. 
The titer of specific anti-P. brasiliensis antibodies58,59,60 
correlates with the severity of the clinical forms, with higher 
levels detected in the acute/subacute and disseminated forms. 
In cases of PCM caused by P. lutzii, such information remains 
unknown, which has motivated multicenter studies in endemic 
areas. PCM cases with false negative results from any of the 
previously mentioned tests are most often associated with very 
localized lesions and hosts with AIDS or immunodepressive 
conditions. Antigens prepared from P. brasiliensis that are 
rich in gp43KDA62 have excellent accuracy in the diagnosis 
of P. brasiliensis infections58-60 , but have a low sensitivity 
in the diagnosis of P. lutzii infections63,64. These serological 
tests display a specificity between 85% and 100%, with 
immunodiffusion having the highest rate of specificity. 
False-positive reactions may occur in sera from patients with 
histoplasmosis, and eventually aspergillosis and leishmaniasis; 
however, gel immunodiffusion provides the highest rate of 
specificity for these conditions. 
Currently, the main method of PCM serological diagnosis 
is double agar gel immunodiffusion (DID) because of its 
simplicity, cost-effectiveness, sensitivity (>80%), specificity 
(>90%), and extensive application over the last decades. For 
DID, or any other test used in the diagnosis of PCM, serums 
should be titrated to increase the accuracy of therapeutic 
response interpretation because antibody titers progressively 
decrease with successful clinical control. To meet serological 
cure criteria, negative or stabilization results at a dilution of 
1:2 or less should be achieved. In certain cases, patients may 
already have titers below 1:4 upon diagnosis; therefore, the 
serological criteria will have limited value during treatment 
follow-up. Additional resources and techniques for PCM 
diagnosis have been developed, but they are not available 
for PCM routine assessment. These examinations include the 
immunoblot technique, the triage ELISA test, the detection of 
specific antigens and PCR65,66.
To date, there are no validated serological techniques for 
the accurate diagnosis of infection by P. lutzii. Unfortunately, 
there is no commercial system available for PCM diagnosis, 
and all available tests are based on systems developed in 
house58-60,63,64. A recent study revealed a large variability in 
the mycosis diagnostic results generated by serological tests 
performed at different reference laboratories67. Thus, to ensure 
precise assessment, follow-up serological response curves 
to antifungal treatments should be performed by the same 
technique and laboratory. 
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Frequency of outpatient visits and completion of  
examinations
During the first 3 months of infection, monthly 
consultations are recommended to optimize patient adherence 
to the established regimen, to assess drug tolerability, and 
to ensure good clinical response (Table 3). If a satisfactory 
clinical response is observed, the consultations should become 
quarterly until the end of the first year. After 90 days of follow-
up if a satisfactory clinical response is observed, patients 
should undergo complete blood count and biochemical 
tests every 3 months during the first year. Radiological and 
serological examinations should be requested every 6 months, 
or at shorter intervals if a satisfactory clinical response is 
not observed or if laboratory results indicate no change in 
activity. The reduction of specific antibody titers should occur 
approximately 6 months after treatment and should be either 
negative or stabilized at low titers for approximately 10 to 
24 months after treatment. These estimations depend on the 
Examinations 1st medical
appointment
1st, 2nd, 
3rd month
6th, 9th, 
12th monh
18th,
24th 
month
≥ 2 years 
6/6 months
>1 year after 
treatment 
interruption: 6/6 
months*
Medical
appointment
X X X X X X
Hemogram, 
ALT, Alkaline 
phosphatase
Na, K creatinine
X 3rd month X X X X
Erythrocyte 
sedimentation rate X X
Serology X 6th,
12th
18th,
24th
X X
Thorax X-ray X X 6th,
12th
X* X* If necessary**
TABLE 3
Guidance for clinical-laboratory follow-up of patients with paracoccidioidomycosis undergoing therapy.
ALT: alanine aminotransferase; Na: sodium; K: potassium. * After 1 year of treatment discontinuation, the patient should be 
released from follow-up if cure criteria has been met. **Thorax X-ray: according to the presence of changes.
clinical form, severity, and antifungal treatment administered, as 
itraconazole promotes a faster response than cotrimoxazole in 
the acute form rather than the chronic form. In the second year of 
follow-up, the consultations should become semi-annual. Once 
the cure criteria have been met, treatment should be discontinued 
and patients should be followed-up on an outpatient basis for up 
to two years. After this period, if the patient continues to meet 
cure criteria, the patient can be released from outpatient follow-
up and instructed to return if necessary. 
According to the clinical presentation of PCM, specific follow-
up examinations, such as ultrasound (e.g. to evaluate the evolution 
of nodal masses or nodular images in abdominal organs), and 
CT, or MRI to evaluate cephalic lesions should be requested.
Clinical specialty outpatient support
Patients with PCM that involves the larynx (dysphonia) 
and trachea should be referred to an otorhinolaryngologist 
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for evaluation and specialized examinations, such as 
nasofibroscopy, for early diagnosis and treatment of 
complications. 
Despite adequate treatment and satisfactory therapeutic 
response, patients who develop persistent dyspnea associated 
with cutaneous and mucosal lesion scarring and body weight 
recovery should be referred to a pulmonologist to treat 
cicatricial lung disease or associated respiratory pathologies. 
Similarly, patients with Addison’s syndrome caused by 
adrenal impairment as a result of active or residual PCM 
should be followed up by an endocrinologist, especially those 
patients who were unresponsive to usual treatments. Patients 
with PCM with neurological, intestinal, or abdominal lymphatic 
involvement, accompanied by malabsorption syndromes, 
reproductive organ lesions, or other clinical situations, should 
be followed-up by a specialized physician because management 
of disease in these patients often presents additional difficulties.
INDICATIONS FOR HOSPITALIZATION
The following types of patients must be hospitalized:
1. Patients with disseminated forms presenting one of 
the following complications: neurological alterations, 
respiratory insufficiency, nutritional status deficiency, 
gastrointestinal involvement, jaundice, ascites, or 
hemodynamic changes. 
• Patients presenting comorbidities, such as AIDS, 
tuberculosis, and/or neoplasia, and if there is a need 
for better diagnostic investigation or observed clinical 
deterioration.
• Patients with sequelae and clinical instability, such as 
decompensated COPD, cor pulmonale, Addison’s disease, 
laryngeal, or tracheal stenosis (Figure 10).
ASSESSMENT OF COMORBIDITIES AND 
IMMUNOSUPPRESSION
Many patients with chronic PCM are smokers and present 
with chronic obstructive pulmonary disease (COPD) prior 
to the diagnosis of mycosis. Other diseases are relatively 
common in patients with PCM, particularly chronic infectious 
parasitic diseases and neoplasias. Predisposing factors of PCM 
are believed to promote the occurrence of certain diseases, 
including tuberculosis, leishmaniasis, Chagas disease, leprosy, 
and strongyloidiasis33. Further, Paracoccidioides spp. may be 
opportunistic in patients with reduced cellular immunity as a 
result of underlying disease or immunosuppressive treatments. 
Tuberculosis
Tuberculosis has been reported in approximately 2% to 
20% of PCM cases, and the disease can be diagnosed before, 
after, or concurrently with PCM. When the two infections occur 
simultaneously, difficulties may arise in the diagnosis, selection 
of antifungal therapy, and recognition of therapeutic response68. 
In patients with lung injuries related to Paracoccidioides spp. 
A B
C
D
E F
FIGURE 10 - Sequelae of PCM in the respiratory system. A and B. Microstomia 
resulting from perioral lesions. C. Tracheostomy as a result of tracheal 
stenosis. D. Chest X-ray showing residual bilateral reticular infiltrate. E and 
F. CT showing post-treatment septal thickening, peripheral reticulation, and 
peribroncovascular thickening. PCM: paracoccidioidomycosis. Reproduction 
with modification: Shikanai-Yasuda, MA, Telles Filho F de Q, Mendes 
RP, Colombo AL, Moretti ML, Grupo de Consultores do Consenso em 
Paracoccidioidomicose. Consenso Brasileiro em Paracoccidioidomicose. Rev 
Soc Bras Med Trop. 2006;39(3):297-31039.
infection, sputum smear microscopy is recommended to 
evaluate the occurrence of tuberculosis, especially when there 
is pulmonary infiltrate affecting the upper lobes.
Cancer
Several studies have reported that between 0.16% and 
14.1% of patients with PCM also present with a neoplasm at 
some point in their lives19. Carcinomas were observed more 
frequently in the lungs, oropharynx, and larynx. Patients with 
Paracoccidioides spp.-related airway lesions may develop 
carcinomas at or near the fungal lesion several years later19. 
Whether PCM represents a risk factor for cancer or if both 
diseases have similar predisposing factors remains controversial. 
In patients with PCM, the frequency of cancer is higher 
in smokers than in nonsmokers69. Diagnostic suspicion is 
fundamental for early diagnosis and treatment because clinical 
manifestations of cancer in patients with PCM can be masked 
by symptoms resulting from sequelae of fungal lesions in the 
lungs, larynx, or pharynx, especially in smokers and alcoholics. 
Less frequently, PCM manifests simultaneously or reoccurs 
with neoplasias, such as lymphoma, leukemia, and pulmonary 
carcinoma19,70. This PCM is probably opportunistic and presents 
with localized lesions, particularly in the lung or disseminated. 
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These patients are generally treated with antifungal therapy and 
any deaths are attributed to neoplasia. In areas endemic to PCM, 
this mycosis should be considered in cases of cancer patients 
experiencing clinical worsening. 
Organ transplantation and  
immunosuppressive therapy 
Opportunistic PCM has been observed in patients with reduced 
cellular immunity as a result of renal or hepatic transplantation, 
use of immunosuppressants, such as corticosteroids and cytotoxic 
and immunobiological drugs for the treatment of several diseases, 
or, in rare cases, primary immunodeficiency. This is exemplified 
by a case report of rheumatoid arthritis and bone sarcoma in which 
the patient was medicated with adalimumab, methotrexate, and 
leflunomide, and presented with lung and bone disease related to 
Paracoccidioides spp. infection20. In a small number of cases, PCM 
manifested a few days to 14 years after kidney transplantation, 
which enabled the evaluation of PCM’s clinical and laboratory 
characteristics under these conditions. Chest X-rays revealed that 
these patients had bilateral nodules18, pulmonary cavitation71,72, 
or bronchopneumonic infiltrate73. Lymphatic impairment was 
uncommon74. In these cases, microbiological diagnosis should 
be preferential because serological tests generally show low 
titers of anti-Paracoccidioides spp. antibodies73,75. As in other 
immunosuppressed patients, unusual clinical and serological 
expressions may confuse and delay the diagnosis of PCM. In 
addition, the response to therapy in renal transplant patients may 
be slow, especially with the administration of oral antifungal 
agents72-74. In half of these cases, death was reported. The use of 
effective and intravenous antifungal agents is thus recommended, 
as well as rigorous monitoring of immunosuppressed patients who 
have been exposed to areas endemic to PCM.
HIV infection and AIDS 
Opportunistic PCM has been observed in HIV-infected 
patients, with up to 1.5% of Brazilian AIDS cases reporting 
simultaneously PCM infection17,76. In these co-infected patients, 
PCM progresses more rapidly and lesions are more widespread, 
involving lymphadenomegaly, umbilicated cutaneous lesions, 
hepatosplenomegaly, pulmonary infiltrates, and lesions of the 
central nervous system and other tissues. Most cases present 
mixed clinical manifestations with lesions predominantly of 
acute/subacute PCM, but with frequent pulmonary lesions, 
which may be atypical43. Many patients have a low CD4 + 
lymphocyte count and may present PCM as the first manifestation 
of AIDS. Although about 30% of the cases do not present anti-
Paracoccidioides spp. antibodies, the fungus is easily recognized 
or isolated in mycological or histopathological examinations. 
HIV/Paracoccidioides spp. co-infection can lead to death, but 
most patients can be cured with intensive antifungal treatment 
combined with antiretrovirals and secondary prophylaxis17. 
Recommendations for patients suspected of  
comorbidities and immunosuppression
1. Request an acid-fast bacilli smear and culture in three 
samples of sputum from patients with pulmonary PCM, 
particularly those patients who present with fever, night 
sweats, and infiltrate and/or cavitation in the upper lobes 
of the lungs.
2. Perform an otorhinolaryngological follow-up in patients 
with laryngeal lesions that persist with dysphonia to perform 
a differential diagnosis with tuberculosis or neoplasia.
3. In patients with pulmonary involvement and declining re-
spiratory function despite appropriate treatment, the fol-
lowing conditions should be considered: bacterial infec-
tion, smoking-related lung disease (COPD), or associated 
neoplasia or sequelae with functional consequences. 
4. Investigate a possible HIV infection in patients with 
suggestive epidemiology and in patients with acute/
subacute or mixed form PCM.
5. In immunocompromised patients, the absence of 
antibodies, even in disseminated disease, does not rule 
out the diagnosis of PCM, which should be investigated 
with microbiological testing, and, if possible, with tissue 
biopsy and histopathological examination.
SEQUELAE
PCM is a systemic disease whose host response to the 
infecting agent consists of chronic granulomatous inflammation 
associated with an overlying fibrosing process. Thus, in addition 
to granuloma formation, there is an increased production of 
cytokines, including TNF-α and TGF-β, which can induce collagen 
and reticulin accumulation in the infected tissue. This fibrosing 
response may then lead to anatomical and functional changes 
in the organs affected during infection, especially the lungs. 
Pulmonary
Despite treatment, chronic PCM may continue to present 
symptoms, such as varying degrees of cough, hyaline expectoration, 
and dyspnea41,42. In addition, changes in spirometry, including an 
obstructive pattern, may also be observed in most cases, which 
is justified by the association of peribronchial fibrotic sequelae 
with the history of smoking in most patients42. A complete lung 
function test may also show air trapping and diffusion reduction, 
which in more severe cases can lead to chronic hypoxemia42. Most 
patients, even after completing treatment, show scarring alterations 
upon imaging tests, especially CT scans44 (Figure 10), which can 
reveal architectural distortion (90%), septal and reticulated 
thickening (88%), centrolobular or parasseptal emphysema 
(82%), bronchial thickening (82%), parenchymal bands (74%), 
scarring in emphysema areas (66%), nodules <3 cm (62%), and 
pulmonary cysts (10%)42. In gasometry, an increased alveolar-
arterial O2 gradient, hypoxemia, and hypercapnia may be present, 
with the latter signaling greater severity. Pulmonary hypertension 
is rare, and secondary to parenchymal changes. 
Adrenal glands
On average, adrenal impairment is observed in 56% of 
autopsied cases, ranging from 48.2% to 80.0%34,36. However, 
15% to 50% of patients undergoing adrenal evaluation 
present with a hampered reserve, despite the absence of 
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clinical manifestations, and 3.5% of these patients present 
with Addison’s disease, which requires frequent hormonal 
replacement therapy throughout one’s life49,50. 
Larynx
Laryngeal sequelae are characterized by dysphonia, as 
hoarseness and alterations in airflow and indicate poor closure 
of the fibrotic vocal cords. These complications are associated 
with an increased risk of pulmonary infections by aspiration and 
even difficulty of socializing because the voice is so altered77. 
Sequelae of the trachea can lead to obstruction of the airway 
and subsequent respiratory insufficiencies that can require 
tracheostomy or even surgical correction of tracheal stenosis. 
Central nervous system
Patients frequently develop motor deficits, convulsive 
syndromes (epilepsy), and/or hydrocephalus. Cerebellar 
impairment occurs in about 20% to 30% of PCM cases with 
neurological involvement, and these cases often rapidly evolve to 
intracranial hypertension, which requires ventricular shunting51,52. 
Neurological forms of PCM have substantial risks for sequelae. 
Skin
Cutaneous sequelae can lead to esthetic and oral mucosa 
alterations and even microstomia, which require special care for 
patient feeding and surgical correction after antifungal treatment. 
Main differential diagnoses Sputum microbiology Sputum cytology Chest X-ray and tomography Serum (antibody/antigen)
PCM –
relapse
+ or –Paracoccidoides -
Recurrence of previous lesions, 
radiological findings of 
activity*
+ For PCM*
+ para PCM
Infectious diseases 
Fungi + or - -
Variable: Chronic 
histoplasmosis, pulmonary 
cryptococcosis, and chronic 
cavitary aspergillosis
+ histoplasmosis,/Aspergillosis 
antibodies,Antigenemia  
+:criptococcosis
Bacteria
Gram +/-
+ or - Culture
-
Alveolar consolidation, air 
bronchogram, sometimes 
interstitial infiltrate -
Tuberculosis
AFB +
+ culture
-
Centerlobular nodules,  distr. 
segmentar or confluent 
micronodules, budding tree 
pattern, cavities: thick walls, 
upper thirds; pleural effusion
-
Neoplasia - + neoplastic cells
Variable, neoplastic cells, with 
higher frequency of nodule or 
solitary mass excavated or not; 
localized atelectasis
-
PCM - sequela - -
Scarring emphysema, 
bronchial thickening, signs 
of interstitial fibrosis, and 
peribroncovascular.
Low titers possible in PCM 
sequelae
TABLE 4
Diagnostic approach to respiratory complaints in treated patients.
PCM: paracoccidioidomycosis;: AFB: acid-fast bacilli; +: positive ; -: negative ; ±: positive or negative. *Consolidation, frosted glass lesions, thick-walled cavities, 
thickening of alveolar septa, nodules, and confluent masses. 
Lymphatic
The sequelae of the abdominal lymphatic system can lead to 
obstructive jaundice, as a result of lymph node involvement in 
the hepatic hilum78 and malabsorption syndrome of proteins and 
fats54,79. The social and economical cost of these complications 
has not been adequately evaluated by the scientific community 
or health authorities.
Evaluation and follow-up of pulmonary sequelae
Patients with PCM that involves the lungs may present with 
persistent respiratory symptoms despite undergoing adequate 
treatment. Thus, the presence of respiratory sequelae in the 
lung that are associated with the pathologies or recurrence of 
PCM should be actively investigated in symptomatic patients80. 
Spirometry should be performed and, in the presence of 
an obstructive disorder, the introduction of bronchodilator 
medication is suggested, following guidelines for the treatment 
of COPD81. Chest X-rays and CTs not only aid in the investigation 
of associated pathologies, such as lung neoplasia, but also aid in 
the diagnosis of disease recurrence (onset or recrudescence of 
lesions with radiological signs of activity, such as nodules and 
masses with cavities and ground glass density nodules). Co-
infections, especially tuberculosis (Table 2 and Table 4), should 
be investigated through microbiological examinations of sputum 
and, if necessary, bronchoalveolar lavage. Arterial blood gas 
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analysis may indicate the need for supplemental oxygen in cases 
of severe hypoxemia (PaO2 <55mmHg), and should be requested 
in patients with hypoxemia measured via pulse oximetry81. In 
more advanced cases from a clinical, spirometric, or laboratory 
point of view, a pulmonologist should perform an evaluation to 
characterize the severity and orientation of the therapy. 
TREATMENT
Unlike other pathogenic fungi, P. brasiliensis and P. lutzii 
are susceptible to most systemic antifungal agents – even 
sulfonamide derivatives can inhibit their growth. There is no 
solid evidence to support primary or secondary resistance to 
the drugs used in PCM treatment. Therefore, several antifungal 
drugs have been shown to be effective in treating different 
clinical forms of the disease, including azole derivatives 
(ketoconazole, fluconazole, itraconazole, voriconazole, 
posaconazole, and isavuconazole82-87), sulfonamide derivatives 
(cotrimoxazole, sulfadiazine, etc.)88, amphotericin B 
(formulations in deoxycholate, lipid and liposomal complex) 
for severe forms89-91, and even terbinafine92. 
Despite the vast therapeutic arsenal available for disease 
management, itraconazole, cotrimoxazole (sulfamethoxazole/
trimethoprim combination), and amphotericin B are more 
commonly used in clinical practice. There is currently no in 
vitro or in vivo evidence showing that PCM by P. brasiliensis 
and P. lutzii respond differently to the antifungal agents used 
in the treatment of the disease. Therefore, the therapeutic 
recommendations are valid for all patients with PCM.
Although Latin America has high PCM incidence, morbidity, 
and mortality rates, only two randomized clinical trials involving 
patients with PCM have been published. However, neither 
study had statistical power capable of identifying crucial 
definitions, such as efficacy, safety, and treatment duration83,86. 
Thus, the suggested guidelines for PCM treatment are based on 
only two prospective, open randomized studies, and multiple 
Drugs Dose Average duration
Itraconazole*
200mg daily
**Children < 30kg e > 5 years, 5 to 10mg/kg/day, adjust dose without 
opening the capsule
9-18 months
Cotrimoxazole*
Trimethoprim, 160mg + Sulfamethoxazole, 800mg (VO 8/8h or 12/12h)
Children –Trimetoprim, 8 to 10mg/kg + Sulfamethoxazole, 40 to 
50mg/kg, VO 12/12h
18-24 months***
Amphotericin B
Deoxycholate 0.5-0.7mg/kg/day (IV)
Lipid formulation 3-5mg/kg/day (IV) 2-4 weeks**** (until improvement) 
TABLE 5
Most commonly used drugs in patients with paracoccidioidomycosis.
CNS: central nervous system. *Do not use concomitantly with astemizole, antacids and H2 blockers, barbiturates, cisapride, cyclosporine, didanosine, digoxin, 
fentanyl, phenytoin, rifampicin, cisapride, and terfenadine. **Increased experience in children with sulfamethoxazole/trimethoprim treatment. ***Extend the 
duration of treatment when there is CNS involvement. ****Requires maintenance treatment with itraconazole or cotrimoxazole.
retrospective or prospective, comparative or non-comparative 
studies82,86,90,93,94. Although tested in a small number of patients, 
voriconazole, posaconazole, and isavuconazole have been shown 
to have inhibitory action in vitro against Paracoccidioides spp. 
isolates, and therefore, these agents are potentially useful in 
the treatment of PCM. However, drug interactions and adverse 
events of prolonged therapy should be taken into account. 
Treatment of patients with mild  
and moderate forms 
Itraconazole at a dose of 200mg daily has been widely used 
in the treatment of mild and moderate forms of PCM with high 
rates of efficacy and safety. Therefore, at present, this triazole is 
the treatment of choice for patients with mild to moderate forms 
of PCM. The duration of treatment may vary from 9 to 18 months, 
with an average duraction of 12 months, and the patient should 
always be evaluated by clinical, immunological, and radiological 
criteria. (Table 5). In general, the tegumentary lesions heal 30 
days after the start of treatment and the lymphadenopathies regress 
between 45 and 90 days. Stabilization of radiological images is 
usually observed after 6 months of itraconazole use. 
As with many triazole fungicides, the absorption of 
itraconazole may be impaired by a number of factors, such 
as drug interactions, achlorhydria, previous gastrectomy, 
alkaline food intake, or fasted state (Table 5, Table 6, 
Table 7, and Table 8). For increased serum levels in adult 
patients, itraconazole capsules should be ingested in a single 
intake after lunch or dinner. Acidic beverages, such as citrus 
juices, can increase the absorption of itraconazole, while 
alkaline foods decrease absorption. Fractionated dosing of 
itraconazole is not recommended because its absorption from 
the gastrointestinal tract occurs only when the drug is packed 
in intact capsules. In terms of clinical efficacy (predominantly 
with chronic PCM), treatment duration and adherence, and 
pharmacoeconomics, several retrospective, comparative studies 
have shown that the treatment of PCM with itraconazole is 
more advantageous than treatment with sulfamethoxazole/
trimethoprim (cotrimoxazole)93,94. 
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Drugs Sulfamethoxazole + Trimethoprim (SXT) Amphotericin B
Azathioprine Risk of leukopenia by medullary suppression Monitor No interactions found 
Aminoglycosides
(amikacin, gentamicin, tobramycin, 
netilmicin, and streptomycin)
No interactions found ↑ nephrotoxicity
Combination contraindicated
Cyclosporine ↓ cyclosporine 
↑ risk of nephrotoxicity
Avoid combination 
↑ nephrotoxicity
↑ ototoxicity
Combination contraindicated
Digoxin ↑ digoxin
Use with caution 
↑ risk of toxicity of digoxin if ↓K
Monitor carefully
Phenytoin ↑ Phenytoin  
Use with caution and monitor 
No interactions found
Isoniazid No interactions found No interactions found
Loperamide No interactions found No interactions found
Methotrexate ↑ toxicity methotrexate
Avoid combination
No interactions found
Metformin ↑Metformin
Minor interaction 
No interactions found
Rifampicin ↓SXT – Monitor No interactions found
Pyrimethamine ↑ risk of megaloblastic anemia Monitor 
Warfarin ↑ Warfarin effect
Avoid combination
No interactions found
Thiazides ↑ risk of thrombocytopenic purpura Monitor No interactions found
TABLE 6
Drug interactions of sulfamethoxazole + trimethoprim and amphotericin B.
K: potassium; SXT: sulfametoxazole-thrimethoprim; References: http://reference.medscape.com/drug-interactioncheck95; https://online.epocrates.com/interaction-
check96.
New azole derivatives
Although only a small number of patients have been treated 
with other drugs on the expanded triazole spectrum triazoles, 
including voriconazole, posaconazole (with expected future 
use with extended release capsules), and isavuconazol, these 
drugs can be considered as potential substitutes for itraconazole 
as their costs become more affordable and new evidence is 
published86,87; however, drug interactions should be taken into 
account95,96 (Table 6, Table 7 and Table 8).
Cotrimoxazole (sulfamethoxazole/trimethoprim) 
Although cotrimoxazole is fungistatic and requires a longer 
treatment duration than that of itraconazole, cotrimoxazole is the 
second treatment option for patients with mild to moderate forms 
of PCM. Cotrimoxazole’s advantages include large availability 
within Brazil’s public health system, tablet form, oral and 
venous formulations, and good absorption with predictable 
serum levels. The oral suspension can be used in children 
who do not tolerate tablets and in adults who do not swallow 
tablets because of stenotic laryngeal or esophagus lesions. The 
cotrimoxazole venous solution can be used in patients with 
digestive disorders and/or who do not absorb oral medication 
well. Cotrimoxazole can also be used in contraindications 
of itraconazole, or in cases of suspected therapeutic failure 
or concomitant tuberculosis treatment. According to a few 
published cases, cotrimoxazole is the treatment of choice for 
patients with neuroparacoccidioidomycosis52,97. 
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Drugs Fluconazole Itraconazole Ketoconazole Voriconazole Posaconazole
Amitriptyline ↑ QT *Avoid 
combination
↑ QT* Avoid 
combination
↑ QT*Avoid 
combination
↑ QT*Avoid 
combination
↑ QT*Avoid 
combination
Warfarin ↑ Warfarin 
Avoid 
combination
↑ Warfarin 
Avoid combination
↑ Warfarin 
Avoid combination
↑ Warfarin 
Avoid combination
↑ Warfarin 
Avoid combination
Calcium channel 
blockers
↑blocker effect 
Combination not 
contraindicated
↑ blocker effect  
Combination not 
contraindicated
↑ blocker effect  
Combination not 
contraindicated
↑ blocker effect  
Combination not 
contraindicated
↑ blocker effect  
Combination not 
contraindicated
H2 blockers, antacids,
sucralfate
No interactions found ↓ Itraconazole  
 Avoid combination
↓ Ketoconazole 
 Avoid combination
No interactions found ↓ Posaconazole 
 Avoid combination
Carbamazepine ↑Carbamazepine 
Monitor serum 
carbamazepine level
Use with caution
↑Carbamazepine 
↓Itraconazole 
Monitor serum 
carbamazepine level
Use with caution
↑Carbamazepine 
↓Ketoconazole 
Monitor serum 
carbamazepine level
Use with caution
↑Carbamazepine 
↓Voriconazole 
Combination 
contraindicated
↑Carbamazepine 
↓Posaconazole 
Monitor serum 
carbamazepine level
Use with caution
Cyclosporine ↑Cyclosporine 
Use with caution
↑Posaconazole 
↑Cyclosporine 
Monitor clinical 
treatment
↑Cyclosporine Monitor 
serum level
↑Cyclosporine 
Monitor serum level
↑Posaconazole 
↑Cyclosporine 
Monitor clinical 
treatment
Phenytoin ↑Phenytoin  
 Use with caution
↓Itraconazole 
Avoid
 combination
↑Phenytoin  
↓Ketoconazole 
Avoid combination
↑Phenytoin  
↓Voriconazole 
 Avoid combination 
or monitor 
↑Phenytoin  
↓Posaconazole 
Avoid combination
Isoniazid No interactions found ↓Itraconazol e Monitor 
serum level
↓Ketoconazole 
Combination 
contraindicated
↑Voriconazole 
Monitor serum level
No interactions 
found
Proton pump 
inhibitors 
(omeprazole)
↑effect of proton 
pump inhibitors  
 Use with caution
↓Itraconazole 
 Avoid combination
↓Ketoconazole  
Combination 
contraindicated
↑ effect of proton 
pump inhibitors  
 Use with caution
↓Posaconazole 
 Avoid 
combination
Lovastatin /
Simvastatin
↑ Lovastatin /
Simvastatin 
Combination 
contraindicated
↑ Lovastatin /
Simvastatin 
Combination 
contraindicated  
Risk of myopathy 
and rhabdomyolysis
↑ Lovastatin /
Simvastatin 
Combination 
contraindicated  
Risk of myopathy and 
rhabdomyolysis
↑ Lovastatin /
Simvastatin 
Combination 
contraindicated  
 Risk of myopathy 
and rhabdomyolysis
↑ Lovastatin /
Simvastatin 
Combination 
contraindicated  
Risk of 
myopathy and 
rhabdomyolysis
Midazolam/
triazolam
 oral
↑ Midazolam 
 Risk of respiratory 
depression Avoid 
combination
↑ Midazolam 
Risk of respiratory 
depression   
Combination 
contraindicated
↑ Midazolam 
 Risk of respiratory 
depression 
Combination 
contraindicated
↑ Midazolam 
 Risk of respiratory 
depression  
 Avoid combination
↑ Midazolam 
 Risk of respiratory 
depression  
 Avoid 
combination
Rifampicin/
rifabutin
↓Fluconazole 
↓Rifampicin 
 Consider increasing 
the dose of 
fluconazole
↓Itraconazole 
↓Rifampicin Monitor 
treatment efficacy
↓Ketoconazole 
↓Rifampicin
Monitor treatment 
efficacy
↓Voriconazole 
↓Rifampicin 
 Combination 
contraindicated
↓Posaconazole 
↓Rifampicin 
Monitor treatment 
efficacy
Sirolimus ↑Sirolimus  
 Combination 
contraindicated
↑Sirolimus  
 Use with caution
↑Sirolimus  
 Combination 
contraindicated
↑Sirolimus  
 Combination 
contraindicated
↑Sirolimus  
 Combination 
contraindicated
Tacrolimus ↑ QT 
↑ Tacrolimus 
 Avoid combination
↑ Tacrolimus 
 Avoid combination
↑ Tacrolimus 
 Avoid combination
↑ Tacrolimus 
 Use with caution
↑ Tacrolimus 
 Use with caution
TABLE 7
Main drug interactions for azole antifungals.
References: http://reference.medscape.com/drug-interactioncheck95; https://online.epocrates.com/interaction-check95;*QT interval in electrocardiogram.
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Antiretroviral Fluconazole Itraconazole Voriconazole Posaconazole
Zidovudine ↓Zidovudine
Minor interaction
No interactions found No interactions found No interactions found
Tenofovir No interactions found No interactions found No interactions found No interactions found
Lamivudine No interactions found No interactions found No interactions found No interactions found
Efavirenz 
(avoid combination with 
azoles)
Minor interaction ↑Efavirenz
↓Itraconazole
↑Efavirenz
↓Voriconazole
↑Efavirenz
↓Posaconazole
Dolutegravir No interactions found No interactions found No interactions found No interactions found
Darunavir ↑Darunavir ↑Darunavir
Avoid combination
↑Darunavir ↑Darunavir
Ritonavir ↑Ritonavir
Use with caution
↑Ritonavir; ↑Itraconazol
Avoid combination
↑Ritonavir; ↓Voriconazole
Combination contraindicated
↑Ritonavir; ↑Posaconazole
Lopinavir/
ritonavir
↑Lopinavir
↑Ritonavir
Avoid combination
↑Lopinavir
↑Ritonavir
↑Itraconazol
Avoid combination
↑Ritonavir
↓Voriconazole
Combination contraindicated
↑Lopinavir
↑Ritonavir
↓Posaconazole
Use with caution
Atazanavir ↑Atazanavir
Minor interaction
↑Atazanavir
↑Itraconazol
Use with caution
↑Atazanavir
Combination contraindicated
↑Atazanavir
Minor interaction
Abacavir No interactions found No interactions found No interactions found No interactions found
TABLE 8
Drug interaction between antiretrovirals and azole antifungals.
References: http://reference.medscape.com/drug-interactioncheck95; https://online.epocrates.com/interaction-check96.
Treatment of patients with severe and  
disseminated forms
For severe and disseminated forms of PCM, amphotericin 
B in deoxycholate or in lipid formulation (liposomal or lipid 
complex) is indicated for use. The recommended induction dose 
of conventional amphotericin B is 0.5-0.7mg/kg/day, with a 
maximum of 50mg/day. Lipid formulations should be prescribed 
at doses of 3 to 5mg/kg/day. The duration of treatment depends 
on the clinical stability of the patient and amphotericin B should 
be administered for the shortest possible time (on average 2 to 
4 weeks). Transition to oral medication during the consolidation 
phase should occur after clinical stabilization once the drug’s 
oral absorption has been confirmed. 
If the lipid formulations of amphotericin B cannot be used, 
intravenous cotrimoxazole formulation is recommended at 
a dose of 800mg/160mg every 8 hours. Despite having little 
clinical experience, intravenous fluconazole (600 to 800mg/
day) can also be a therapeutic option.
The main therapeutic challenges of PCM management are 
the continuous use of systemic antifungal agents for extended 
periods, the possibility of relapse, and the appearance of 
sequelae, mainly in the respiratory tract. In addition to the use of 
antifungal drugs, PCM therapeutic management should include 
measures that improve the patient’s general condition, treatment 
of infectious or non-infectious comorbidities, application of cure 
criteria, and post-therapeutic follow-up.
Corticosteroids
Although scarce, there is evidence in the literature that some 
patients with PCM may benefit from the use of corticosteroids 
concomitantly with antifungal treatment98. Patients that have 
been shown to benefit from this approach often have intense 
inflammation, either in the ganglia or central nervous system, 
serious lesions of the larynx or trachea, and lung lesions resulting 
in respiratory insufficiency. The use of prednisone for 1 to 2 
weeks can reduce inflammation during therapy with antifungal 
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agents. In patients with PCM and AIDS who are administered 
antifungal and antiretroviral drugs but still present with worsening 
clinical symptoms, the possibility of immune reconstitution 
inflammatory syndrome (IRIS) may be taken into account, based 
on other infections associated with  HIV/AIDS.  
General measures
All patients should be treated long enough to reduce 
signs and symptoms, stabilize body weight, have clear chest 
X-rays, and appropriate serum antibody titers. In addition to 
specific antifungal therapy, patients with severe forms of PCM 
need general measures to improve their nutritional status and 
immunosuppression. Regulating smoking, alcohol consumption, 
adrenal insufficiency, and other associated conditions also 
contribute to a better patient outcome. Therefore, the following 
factors are important in achieving PCM cured criteria: rest, a 
hyperproteic and hypercaloric diet supplemented with vitamins, 
alcohol and tobacco restriction, and treatment of Addison’s 
disease and associated infections, such as enteroparasitoses 
and respiratory bacterial co-infections. However, these 
recommended measures are useless if the patient cannot access 
antifungal medication, which the majority of the individuals 
with PCM cannot do because of their socioeconomic status 
and inability to afford treatment. Therefore, in the future, 
outpatient medications (itraconazole and cotrimoxazole) should 
be provided free of charge. 
Therapy in special populations
Pregnancy
PCM can occur in pregnant women either as an initial 
manifestation or as a reactivation of a previously controlled 
fungal disease. PCM is believed to occur in pregnant women 
because of the reduction of immune responses in pregnancy, 
which also predisposes these women to other systemic mycoses. 
In one study, Paracoccidioides spp. disseminated to the 
placenta, but there were no reports of fetal involvement99. PCM 
in pregnant women is controllable with the usual antifungal 
agents, primarily amphotericin B (category B). However, with 
the possibility of a teratogenic effect, the use of azole drugs 
(category C) and sulfamethoxazole/trimethoprim (category 
D) should be avoided100. Amphotericin B (category B) and 
sulfadiazine (category C) are alternatives for use during all 
gestational periods, but sulfadiazine should be discontinued 
15 days before the expected delivery date to avoid neonatal 
complications. Sulfamethoxazole/trimethoprim may be 
used during breastfeeding100. Antifungal therapy should be 
maintained throughout all gestational periods to prevent relapse 
and postpartum discontinuation should be assessed by the usual 
cure criteria. After birth, conventional antifungal therapy should 
be administered until the patient reaches the cure criteria.
AIDS
Patients with AIDS generally have severe and widespread 
forms of PCM; therefore, these patients should be initially 
treated with amphotericin B or, if appropriate, with high doses 
of itraconazole, 600mg/day (with attention towards interactions 
with antiretroviral drugs) or intravenous sulfamethoxazole/
trimethoprim (2 ampoules every 8 hours). Despite having limited 
clinical experience, intravenous fluconazole (600-800mg/day) 
may be a therapeutic option. To avoid possible drug interactions, 
PCM should be treated initially with antifungals for 3 to 5 
weeks prior to initiation of antiretroviral therapy. Following the 
cure of PCM, secondary prophylaxis with sulfamethoxazole 
(1,600mg/day), trimethoprim (320mg/day), or itraconazole 
(200mg/day) is recommended based on the treatment of other 
mycoses in immunocompromised patients. Prophylaxis should 
continue until the administered antiretroviral therapy elevates the 
CD4 lymphocyte count to a minimum of 100 cells/μL (concomitantly 
with undetectable viral load) to 200 cells/μL, regardless of viral load 
for at least 3 months. The use of sulfamethoxazole/trimethoprim 
(800/160mg every 12 hours) is also effective as a primary and 
secondary prophylaxis for pneumocystosis and as primary 
prophylaxis for neurotoxoplasmosis. In immunosuppressed 
patients, the absence of antibodies, even in disseminated disease, 
does not rule out the diagnosis of PCM, which should be 
investigated with microbiological tests and, if possible, with tissue 
biopsy and histopathological examination. 
Hepatic or renal insufficiency
The doses of the drugs used in PCM treatment should be 
adjusted in patients with hepatic or renal impairment. 
Renal insufficiency101-103
Amphotericin B
This drug should be avoided because of its high potential 
for nephrotoxicity, which is compounded with the use of 
consecutive series. Serum amphotericin B levels are not 
significantly affected by hemodialysis and do not require 
adjustment in these cases. One should opt for other drugs or a 
lipid formulation of amphotericin B. 
Azoles
Since several azoles present renal excretion, their dose 
should be adjusted as follows101-103.
Fluconazole: this azole has 80% renal clearance, and when 
renal clearance is less than 50ml/min, the dose should be reduced 
to 50% and administered at intervals of 48 hours. If renal 
clearance is less than 20 ml/min, the dose should be reduced 
to one-third of the normal dose and administered at intervals 
of 72 hours. In the case of hemodialysis, the full dose should 
be used after the dialysis process and 50% of the normal dose 
should be used during peritoneal dialysis.
Itraconazole: when renal clearance is less than 10ml/min, 
the dose should be reduced to 50%. In the case of hemodialysis 
or peritoneal dialysis, 100mg of an oral solution should be 
administered every 12 to 24 hours.
Voriconazole: when creatinine clearance is more than 50ml/
min, use a 6mg/kg loading dose every 12 hours twice, followed 
by a 4mg/kg/day every 12 hours. Do not use an IV solution when 
clearance is less than 50ml/min. In cases of renal replacement 
therapy, hemodialysis, or peritoneal dialysis use 4mg/kg/day 
every 12 hours.
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Terbinafine: when clearance is greater than 50ml/min, 
administer a dose only every 24 hours, and avoid use when 
clearance is less than 50ml/min.
Sulphamidic derivatives
Sulphamidic derivatives present renal excretion and their 
metabolites may cause toxicity because they are poorly soluble 
at an acidic pH (urine), resulting in the formation of crystals that 
are deposited in the renal tubules that can lead to obstruction 
and subsequent kidney damage. Cases of interstitial nephritis 
have also been reported. These derivatives can be removed by 
dialysis. As a result, these products should be avoided in patients 
with renal insufficiency.
Functional liver changes101-104 
PCM can cause functional liver changes via hepatocytic 
injury or extrinsic cholestatic compression104. In these cases, 
PCM treatment follows the proposed standards and the 
patient typically exhibits satisfactory responses. However, 
hepatotoxicity induced by antifungal agents may occur. 
Amphotericin B
This drug has been known to accumulate in organs, often 
remaining in the liver, but rarely leading to an increase in 
transaminases. Amphotericin B deoxycholate is slightly 
hepatotoxic, unlike its lipid derivatives, which have the 
disadvantage of displaying a higher hepatic toxicity. Liver 
failure does not cause significant retention of the drug, which 
maintains a stable serum level. 
Azoles
The biochemical changes observed with itraconazole persist 
with continued treatment. In treatment with cotrimoxazole and 
itraconazole, the commonly reported biochemical changes do 
not exceed 5x the upper limit of normality, which allows the 
maintenance of the treatment. However, there are case reports 
in which itraconazole had to be discontinued. Of the azoles, 
fluconazole is the least hepatotoxic. 
Metabolized in the liver with contraindications  
relating to serious liver diseases
Ketoconazole, voriconazole and Sulphonamides
Voriconazole and ketoconazole are the most hepatotoxic 
agents, followed by itraconazole105. Therefore, these agents 
should be avoided in cases of severe hepatic impairment. 
Fluconazole can be used with great caution if the patient cannot 
be treated with amphotericin. 
Metabolized in the liver with adjusted doses  
relating to liver diseases
Voriconazole should be administered at 6mg/kg every 12 hours 
for two doses, followed by a dose of 2mg/kg/day every 12 hours. 
Sulphamidic derivatives 
These agents rarely cause severe hepatotoxic injury, and may 
be used. Despite treatment maintenance, liver toxicity induced 
by cotrimoxazole evolves with the normalization of serum 
liver enzymes. In patients with hepatic impairment caused by 
other conditions, such as cirrhosis or alcoholic liver disease, 
amphotericin B deoxycholate should be used because it is less 
toxic to the liver than other preparations. An alternative agent 
is fluconazole. 
Paracoccidioidomycosis in children39,40,106,107
In children infected with PCM, the most commonly used 
treatment is the combination of sulfamethoxazole/trimethoprim 
because it has known efficacy, good tolerability, syrup-like 
presentation for dose administration and adequacy, and is 
provided by the public health network39,40,106. The recommended 
dose ranges between 8 to 10mg/kg/day of trimethoprim in two 
daily doses, and no fasting is required. Intravenous formulation 
is an alternative when the oral route is contraindicated, as in 
cases of intestinal subocclusion. The intravenous formulation 
should be administered at the same dosage twice a day. Among 
the side effects reported, leukopenia is frequent; however, 
this condition can be controlled without other associated 
complications with the concomitant use of folinic acid106. 
Itraconazole may be used as a second option at a dose of 5 
to 10mg/kg/day once daily. Amphotericin B deoxycholate, as 
well as other formulations of amphotericin B, is reserved for 
severe cases108. During treatment, some patients may present 
with a paradoxical reaction characterized by clinical worsening, 
such as new lymph node enlargements, fistulization, fever, and 
weight loss. In this case, steroids should be administered108.
Paracoccidioidomycosis in situations  
of limited resources
In Rondônia, a systematic registry of PCM cases has been 
maintained since 1997, with periods of more than 15 cases per 
100,000 inhabitants occurring over the years. In the stratified 
analysis by municipality, periods of almost 40 cases per 100,000 
inhabitants were documented in the southern region of the 
state14.
Individuals with PCM who are rural workers with low levels 
of education, precarious socioeconomic statuses, and difficulty 
assessing health care services are susceptible to delayed 
diagnoses, which may contribute to the disease’s aggravation 
with evolution to sequelae. In Rondônia, about one-third of 
the patients with PCM had a diagnosis based on clinical-
epidemiological criteria14, as serological examination was not 
an available method during this period. In the last 4 years, data 
on more than 100 PCM cases treated at the Tropical Medicine 
Center of Rondônia showed a predominance of the chronic form 
with frequent mucosal involvement. Further, treatment usually 
began approximately 7 months after infection and persisted until 
a therapeutic response from both cotrimoxazole and itraconazole 
was observed. The expansion of the diagnostic network; the 
standardization and availability of antigens of the different 
species described to perform serological tests; the training of 
health professionals, often from other states and still not aware 
of the regional importance of PCM; and the availability of easy-
to-administer medicines by the public authorities, can contribute 
to a better approach to the disease.
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Criteria for cure
After the diagnosis of PCM has been confirmed, treatment 
involves long-term regimens with periodic follow-up, usually on 
an outpatient basis. The duration of therapy should be evaluated 
according to the cure criteria based on clinical, mycological, 
radiological, and immunological parameters. 
Clinical criteria
Cure clinical criteria for PCM include the absence or regression 
of disease signs and symptoms of the disease, such as the healing of 
tegumentary lesions, involution of adenomegaly, and stabilization 
of body weight. The patient’s oral lesions subjectively improve 
after 2 weeks of initial treatment, and after 1 month, there is lesion 
scarring. In addition, skin lesions also regress after 1 month and 
lymphadenomegaly occurs between 2 and 3 months. It is common 
to observe the persistence of residual symptoms or sequelae 
as a result of lesion scarring and fibrosis. The most commonly 
observed sequelae occur in the lungs, lymphatic system, adrenals, 
and CNS. Signs and symptoms resulting from sequelae should 
be differentiated from the clinical presentation of active disease. 
Mycological criteria
Negative direct mycological examination in clinical 
specimens occurs early if treatment is effective. This parameter 
is more easily verified when examining respiratory secretions. 
In other materials, such as biopsies or lymph node secretions, 
fungal assessment is unnecessary because the lesions regress 
or disappear with treatment. 
Radiological criteria
Pulmonary opacities, initially of nodular, micronodular, or 
reticular pattern, and cavitary lesions tend to become linear 
images, indicating pulmonary lesion scarring and fibrosis. The 
stabilization of pulmonary radiological image patterns should 
be analyzed in semiannual chest X-rays (Table 3). 
Immunological criteria
The most commonly used serological method for detecting 
antibodies is the DID reaction. An antibody titer is expected 
to be negative or stabilized at low levels with treatment 
(undiluted serum or 1:2 dilution). Alternatively, when using 
counterimmunoelectrophoresis (CIE), stabilization occurs in 
undiluted serum until a 1:4 dilution. Serological evaluations 
should be conducted every 6 months, when available. 
Post-treatment follow-up 
The term definitive cure can never be applied to patients 
with PCM because P. brasiliensis cannot be eradicated 
from the organism. Therefore, the aim PCM treatment is to 
reduce the fungal load in the patient’s body, allowing cellular 
immunity and the balance between parasite and host to recover. 
After treatment and the observation of cure criteria, patients 
should undergo outpatient follow-up with routine clinical and 
serological evaluation. Clinical relapse can be indicated by a 
positive titer or increase in the DID titer value. Periodic clinical 
examination with weight control and verification of oral lesion or 
lymphadenopathy occurrence should be performed for a period 
of up to 1 year after achieving the cure criteria. 
CONTROL, PREVENTION,  
CHALLENGES, AND RECOMMENDATIONS 
Control and prevention
Currently, a vaccine to prevent Paracoccidioides spp. infection 
in humans is not available, although promising results have been 
observed in laboratory animals109. Recommendations for the 
prevention of PCM derive from knowledge of the most obvious 
infection situations, which occur as a result of aerial exposure to 
conidia in endemic areas and predisposing risk factors.
In both rural and periurban environments, inhabitants should 
avoid exposure to dust from soil excavation, earthworks, and 
plant manipulation. For rural workers and tractor drivers who 
are constantly exposed to the dense dust, such as those who 
perform hand-picking, cleaning (sweeping), and coffee sweeping, 
exposure should be avoided by using well-sealed cabin machines 
or N95 respirators (not always available). In practice, the 
replacement of manual coffee sweeping with an oven may have 
contributed to an observed decrease in PCM incidence among the 
former coffee regions. Further, children and immunosuppressed 
individuals are advised to avoid to situations of risk in rural 
areas. In laboratories, the manipulation of fungal isolates should 
be performed in a safety hood, especially if the cultures are 
in the mycelium form. For laboratories that routinely handle 
Paracoccidioides spp., pre-exposure and annual serological 
examination of researchers is recommended to monitor possible 
fungal infection. Accidents in a research laboratory involving 
transdermal inoculation of Paracoccidioides spp. should be 
managed by monitoring the presence of antifungal antibodies 
in the affected person at the time of suspected infection, after 
3 months, and after 6 months. Prophylaxis with itraconazole 
should be administered orally at 200mg/day for 30 days.
Since chronic PCM has been shown to be associated 
with both smoking and average alcohol consumption16, 
smoking and excessive alcohol consumption (and subsequent 
malnutrition) should be avoided before and after exposure. 
Patients immunosuppressed by drugs and/or transplants20,110 
have an increased risk of developing PCM. Since a case 
report has described the transmission of supra-renal PCM 
through kidney donation111, prior evaluation of organs from 
donors suspected of having epidemiological antecedents is 
recommended. Respective donor recipients suspected of having 
epidemiological antecedents should also be evaluated before 
and during immunosuppression via a chest radiograph and 
Paracoccidioides spp. antibody test. 
Challenges
In addition to improving the prevalence and incidence 
rates of PCM, there are a number of new challenges in the 
management of the disease, such as the registration of cases 
by compulsory notification and notification through drug 
access in outpatient and inpatient cases, standardization of 
serological methods, critical evaluation of antifungal therapies 
and corticosteroid use, search for new therapeutic approaches 
for sequelae, the P. brasiliensis complex, and the description 
of a new species of Paracoccidioides, P. lutzii. 
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For the clinician, it is important to evaluate the current 
epidemiological, clinical, diagnostic, and therapeutic impact 
of the different species on the human disease. For instance, 
the north and midwest regions have been associated with PCM 
infections caused by P. lutzii because of molecular identification 
of isolates in these areas1,5,9 and higher sera reactivity of patients 
with proven disease in these areas to P. lutzii antigen63,64. 
Although clinical data and therapeutic response are similar 
for both species (data from Mato Grosso do Sul), little is 
known about the isolation and molecular identification of the 
species in patients8 because mycological and histopathological 
examinations cannot distinguish these species and molecular 
tests are not available in routine laboratories66. 
The following issues remain unanswered: knowledge of the 
epidemiological-molecular profile of Paracoccidioides isolates 
in Brazil to enhance the clinical-epidemiological diagnosis; 
characterization of the antigenic profile of the isolates and their 
correlation with clinical-laboratory data of disease caused by 
both species1,7, including sequelae and response to different 
drugs, as well as analysis of drug susceptibility112,113. 
Of great importance to public health is the introduction of 
simple methods, such as mycological examination, that can serve 
as the first choice in diagnosis in poor regions. These methods 
would be especially useful in cases where tuberculosis diagnosis 
is excluded. However, this requires the joint effort of public 
agencies and the academic community to develop a serological 
diagnosis that is universally available for both P. lutzii and P. 
brasiliensis infections, with stable antigenic fractions and easily 
reproducible tests. The international academic community has 
united the endemic Latin American countries to create the 
Latin American Network of Paracoccidioidomycosis through 
the Working Group on Paracoccidioidomycosis114 to overcome 
these challenges. The dissemination of knowledge collected 
from clinical-epidemiological, mycological, and serological 
data in all endemic regions is also a fundamental step for the 
early diagnosis, treatment, and establishment of comprehensive 
patient care. 
Recommendations
The following are general recommendations for improving 
the care of patients with PCM:
1. Institute a compulsory notification of cases with probable 
and proven PCM;
2. Create a national registry of cases through notification via 
access to medicine or hospitalization;
3. Enable universal access to itraconazole and cotrimoxazole 
for treatment of mild to moderate forms;
4. Enable access to lipid formulations of amphotericin in 
special situations, such as immunosuppression, and to 
amphotericin B deoxycholate, which has been released 
for marketing after receiving approval of minimum 
pharmacological requirements;
5. Structure a basic care network based on clinical-
epidemiological, mycological (direct and cultural), and 
serological diagnosis;
6. Facilitate access to histopathological diagnosis in the 
absence of mycological diagnosis; 
7. Provide stable and reproducible antigens of P. brasiliensis 
and P. lutzii in the public health network;
8. Standardize a serological technique for diagnosis and 
follow-up at the national level;
9. Stimulate the evaluation of the role of corticosteroids in 
the treatment of patients with intense and/or extensive 
inflammatory lesions;
10. Enhance the evaluation of antifungal maintenance therapy 
in immunosuppressed patients according to the degree of 
immunodepression;
11. Determine the appropriate moment to introduce antiretroviral 
therapy to AIDS patients, considering the presence of drug 
interactions and possibility of IRIS, and establishing the 
parameters for such evaluations;
12. Create a data bank on the distribution of the different 
species of Paracoccidoides in the country to be used in 
epidemiological diagnoses and to launch multicentric 
projects with serological tests and typing of isolates with 
the support of consolidated groups and network projects.
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